Stock Traders Buy High Volume of SIGA Technologies Call Options (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGA) saw unusually large options trading activity on Wednesday. Investors bought 1,200 call options on the stock. This represents an increase of 1,438% compared to the average daily volume of 78 call options.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP acquired a new position in SIGA Technologies in the third quarter valued at about $757,000. AltraVue Capital LLC increased its holdings in SIGA Technologies by 6.6% during the 2nd quarter. AltraVue Capital LLC now owns 2,177,646 shares of the company’s stock worth $16,528,000 after purchasing an additional 134,450 shares in the last quarter. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of SIGA Technologies by 152.6% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,048,440 shares of the company’s stock valued at $13,827,000 after purchasing an additional 1,237,620 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new position in shares of SIGA Technologies during the third quarter worth about $1,098,000. Finally, Foundry Partners LLC bought a new position in shares of SIGA Technologies during the third quarter worth about $2,801,000. Institutional investors and hedge funds own 55.40% of the company’s stock.

SIGA Technologies Stock Down 0.2 %

SIGA stock opened at $6.28 on Thursday. The firm has a 50 day moving average of $6.57 and a two-hundred day moving average of $7.63. SIGA Technologies has a 12 month low of $4.26 and a 12 month high of $12.83. The company has a market capitalization of $448.42 million, a price-to-earnings ratio of 5.23 and a beta of 0.94.

SIGA Technologies (NASDAQ:SIGA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.02 earnings per share (EPS) for the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%. The business had revenue of $10.01 million for the quarter. On average, research analysts expect that SIGA Technologies will post 1.04 EPS for the current fiscal year.

SIGA Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.